Research with NV-387 Showing Promising Results Against Multiple Viruses
May 9, 2024
NanoViricides Reports Promising Results for NV-387 in Influenza A H3N2 Mouse Model
June 27, 2024
NanoViricides Broad Spectrum Technology Represents Potential Paradigm Shift in
Viral Therapy…
Viral Therapy…
Zacks Small-Cap Research (NOTE)
Novel anti-viral could boost a US$3 bln market
Proactive Research
Nanoviricides Investigates NV-387 for MPOX Treatment Amid Global Outbreak
Sept. 9, 2024
Press Releases
NanoViricides Product Pipeline
COVID
Sars-Coronavirus
MERS
RSV
SMALLPOX
VZV "SHINGLES
DERMAL TOPICAL
CREAM
HSV -1
"GENITAL LESIONS"
HSV-2
"COLD SORES"
HIVCIDE
Potentially
"Functional Cure"
EBOLA, MARBURG,
HEMORRHAGIC
VIRUSES
DENGUE VIRUS
RABIES
HEPATITIS C
MANY MORE
TO COME
Company Fact Sheet
A New Era in Targeted Anti-Viral Therapeutics
Imagine coursing through the blood stream, chasing through the body, grabbing and destroying the offending virus particles. NanoViricides, Inc. is striving to bring this imagination to fruition. A nanoviricide®, as defined by the Company, is a nanomachine that is armed to destroy a particular kind of virus. Which virus? That information is programmed into the nanoviricide, akin to the postal address on an envelope.
Biomimetic Technology to "Fool" Viruses
A "nanoviricide" is an agent designed by the Company to fool a virus into attaching to this antiviral nanomachine, in the same way that the virus normally attaches to the receptors on a cell surface. Once attached, the flexible nanoviricide glob wraps around the virus and traps it. In the process, the virus also loses its coat proteins that it needs to bind to a cell. The virus is thus neutralized and effectively destroyed. A nanoviricide completes the task of dismantling the virus particle without immune system assistance. This is the putative or designed mechanism of action of a nanoviricide. Thus nanoviricides represent the next great advance in "Immunotherapeutics" (antibodies and vaccines), which are currently well established antiviral strategies.
NanoViricides In the News
01-23-2020
By - Kennedy
08-21-2018
By - Uptick Newswire
08-24-2016
By - CT Post NewsTimes
Presentations and Abstracts
09-20-2024
06-26-2018
06-24-2017
Anil R. Diwan
Executive Chairman, President
Dr. Diwan invented novel polymeric micelle-based nanomedicine technologies
Meeta Vyas
Chief Financial Officer
Ms. Vyas was First Indian woman to be named CEO of a publicly listed US corporation
Randall Barton
Chief Scientific Officer - Consulting
Dr. Barton has over 25 years experience in drug discovery and development
Jayant Tatake
Vice President, R&D
Jay Tatake has over 25 years of experience in Organic Chemistry, Research and Process Development.